Menu
Montecito
Pac Premier
Giving Guide
Loading...
You are here:  Home  >  'Zarxio'
Latest
Premium Content

FDA gives big win to Amgen in biosimilars race

By   /  Friday, September 30th, 2016  /  Central Coast Health Watch, East Ventura County, Latest news  /  Comments Off on FDA gives big win to Amgen in biosimilars race

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

CVS Health will not cover Amgen’s Neupogen in favor of Novartis biosimilar

By   /  Thursday, August 4th, 2016  /  Central Coast Health Watch, Latest news  /  Comments Off on CVS Health will not cover Amgen’s Neupogen in favor of Novartis biosimilar

CVS Health will no longer cover Thousand Oaks-based Amgen’s Neupogen on its standard drug plan in 2017, favoring the biosimilar Zarxio from Novartis. CVS, which is the second largest benefits manager behind Express Scripts and also owns the largest chain of drug stores in the U.S., said Aug. 2 it will choose biosimilar drugs over Read More →

Read More →
Latest

Amgen shares drop as Novartis launches cheaper drug

By   /  Thursday, September 3rd, 2015  /  Central Coast Health Watch, East Ventura County, Latest news, Top Stories, Tri-County Public Companies  /  Comments Off on Amgen shares drop as Novartis launches cheaper drug

Amgen, the giant biotech company based in Thousand Oaks, saw its shares drop 2 percent to $149.23 on Sept. 3 after its rival Novartis launched a drug similar to Amgen’s that costs 15 percent less. Novartis’ Zarxio and Amgen’s Neupogen both help chemotherapy patients battle infections by increasing the production of white blood cells. The Read More →

Read More →